IL164317A0 - Statin therapy for enhancing cognitive maintenance - Google Patents

Statin therapy for enhancing cognitive maintenance

Info

Publication number
IL164317A0
IL164317A0 IL16431703A IL16431703A IL164317A0 IL 164317 A0 IL164317 A0 IL 164317A0 IL 16431703 A IL16431703 A IL 16431703A IL 16431703 A IL16431703 A IL 16431703A IL 164317 A0 IL164317 A0 IL 164317A0
Authority
IL
Israel
Prior art keywords
statin
statin therapy
enhancing cognitive
galantamine
active ingredient
Prior art date
Application number
IL16431703A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL164317A0 publication Critical patent/IL164317A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
IL16431703A 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance IL164317A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (1)

Publication Number Publication Date
IL164317A0 true IL164317A0 (en) 2005-12-18

Family

ID=28675573

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16431703A IL164317A0 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance
IL164317A IL164317A (en) 2002-04-02 2004-09-28 Pharmaceutical compositions comprising statin for use in the treatment of patients suffering from memory disorder, and a process for making the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL164317A IL164317A (en) 2002-04-02 2004-09-28 Pharmaceutical compositions comprising statin for use in the treatment of patients suffering from memory disorder, and a process for making the same

Country Status (21)

Country Link
EP (1) EP1492539B1 (https=)
JP (1) JP2005525391A (https=)
KR (1) KR100986194B1 (https=)
CN (1) CN100528164C (https=)
AT (1) ATE331523T1 (https=)
AU (1) AU2003226753B2 (https=)
BR (1) BR0308293A (https=)
CA (1) CA2480275C (https=)
CY (1) CY1105545T1 (https=)
DE (1) DE60306503T2 (https=)
DK (1) DK1492539T3 (https=)
EA (1) EA013069B1 (https=)
ES (1) ES2268393T3 (https=)
IL (2) IL164317A0 (https=)
MX (1) MXPA04009535A (https=)
NO (1) NO20044698L (https=)
NZ (1) NZ536111A (https=)
PL (1) PL211160B1 (https=)
PT (1) PT1492539E (https=)
UA (1) UA79605C2 (https=)
WO (1) WO2003082298A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
WO2005123068A2 (en) * 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
NO20044698L (no) 2004-10-29
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
PL371551A1 (en) 2005-06-27
EP1492539A1 (en) 2005-01-05
AU2003226753A1 (en) 2003-10-13
CN100528164C (zh) 2009-08-19
AU2003226753B2 (en) 2007-06-28
JP2005525391A (ja) 2005-08-25
CA2480275A1 (en) 2003-10-09
EA200401295A1 (ru) 2005-02-24
WO2003082298A1 (en) 2003-10-09
CA2480275C (en) 2011-08-16
NZ536111A (en) 2006-03-31
EP1492539B1 (en) 2006-06-28
CN1642555A (zh) 2005-07-20
KR100986194B1 (ko) 2010-10-07
DE60306503D1 (de) 2006-08-10
CY1105545T1 (el) 2010-07-28
BR0308293A (pt) 2004-12-28
UA79605C2 (en) 2007-07-10
KR20040096608A (ko) 2004-11-16
PL211160B1 (pl) 2012-04-30
PT1492539E (pt) 2006-11-30
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
ES2268393T3 (es) 2007-03-16
ATE331523T1 (de) 2006-07-15
MXPA04009535A (es) 2005-01-25
HK1079688A1 (zh) 2006-04-13

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ATE273693T1 (de) Proteinhaltige arzneimittel
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
TW200633694A (en) Composition and method for treating asthma
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
WO2003066806A3 (en) Therapeutic use of aziridino compounds